Baxter (BAX) Q4 Earnings: What To Expect

Baxter (BAX) Q4 Earnings: What To Expect

Radek Strnad

Wed, February 11, 2026 at 12:03 PM GMT+9 2 min read

In this article:

BAX

+0.97%

Healthcare company Baxter International (NYSE:BAX) will be reporting earnings this Thursday before market open. Here’s what investors should know.

Baxter missed analysts’ revenue expectations by 1.4% last quarter, reporting revenues of $2.84 billion, up 5% year on year. It was a softer quarter for the company, with a significant miss of analysts’ full-year EPS guidance estimates and revenue guidance for next quarter missing analysts’ expectations significantly.

Is Baxter a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Baxter’s revenue to grow 2.2% year on year to $2.81 billion, improving from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $0.54 per share.

Baxter Total Revenue

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Baxter has missed Wall Street’s revenue estimates six times over the last two years.

Looking at Baxter’s peers in the medical devices & supplies - diversified segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Neogen’s revenues decreased 2.8% year on year, beating analysts’ expectations by 7.2%, and Stryker reported revenues up 11.4%, topping estimates by 0.8%. Neogen traded up 30.4% following the results while Stryker was also up 4.3%.

Read our full analysis of Neogen’s results here and Stryker’s results here.

Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the medical devices & supplies - diversified stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. Baxter is up 8.3% during the same time and is heading into earnings with an average analyst price target of $22.90 (compared to the current share price of $21.82).

P.S. STOP buying the AI stocks everyone’s talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.

Terms and Privacy Policy

Privacy Dashboard

More Info